The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
180
6-month treatment of Simvastatin combined with Amlodipine besylate
6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
6-month treatment of Amlodipine besylate combined with Spironolactone
No. 10 Changjiang River Branch, Yuzhong District，Chongqing, China
Chongqing, Chongqing Municipality, China
RECRUITINGchanges in plasma aldosterone levels
blood samples are collected at baseline and 6 months after treatment to measure plasma aldosterone levels， and compare between groups and within groups (pg/ml)
Time frame: 6 month
changes in 24-hour urinary aldosterone levels
24 hours urine are collected at baseline and 6 months after treatment to measure 24-hour urinary aldosterone， and compare between groups and within groups(pmol/24h)
Time frame: 6 month
changes in office blood pressure and home blood pressure
Record office blood pressure at baseline and at follow-up after medical treatment (mmHg), and compare between groups and within groups
Time frame: 6 month
changes in serum potassium levels
blood samples are collected at baseline and 6 months after treatment to measure serum potassium levels， and compare between groups and within groups (mmol/L)
Time frame: 6 month
changes in serum renin level
blood samples are collected at baseline and 6 months after treatment to measure serum renin levels, and compare between groups and within groups (mU/L)
Time frame: 6 month
changes in plasma cholesterol levels
blood samples are collected at baseline and 6 months after treatment to measure plasma cholesterol levels， and compare between groups and within groups (mmol/L)
Time frame: 6 month
changes in blood glucose
blood samples are collected at baseline and 6 months after treatment to measure blood glucose， and compare between groups and within groups (mmol/L)
Time frame: 6 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.